Cimetidine in the treatment of gastric ulcer: review and commentary.
Cimetidine therapy in gastric ulcer disease has been evaluated in four complete and one incomplete controlled, double blind trials. A sixth trial, still under way, is partially blind. Treatment duration ranged from 2 to 6 weeks; doses ranged from 0.8 to 1.2 g daily. Two studies also evaluated the influence of hospitalization on ulcer healing and symptoms. Relatively large doses of antacid taken with cimetidine confounded the evaluation of cimetidine efficacy in two of the trials, without answering the question of antacid efficacy. Cimetidine was more effective than were small doses of antacid in healing ulcers in one study but was not significantly superior to treatment with larger quantities of antacid in two other trials. Preliminary results indicate that cimetidine is more effective than carbenoxolone in healing ulcers. Hospitalization for 2 and 3 weeks conferred no advantage, but patients were not randomly assigned to hospitalization. Definitive studies on whether cessation of cimetidine therapy is followed by accelerated ulcer recurrence have not been reported. The efficacy of chronic or intermittent cimetidine therapy has not been studied in gastric ulcer disease.
D000863:Antacids / Q000627:therapeutic use; D002927:Cimetidine / Q000627:therapeutic use*; D006146:Guanidines / Q000627:therapeutic use*; D006760:Hospitalization; D006801:Humans; D010146:Pain / Q000188:drug therapy; D012008:Recurrence; D013276:Stomach Ulcer / Q000188:drug therapy*
D000863:Antacids; D006146:Guanidines; D002927:Cimetidine